• book
    0% of Lymphomas completed

From the Publisher

This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of lymphoma subtypes.

Lymphoma includes:

Details the most current management across the spectrum of lymphoma subtypes
Expert contributors from across the US and Canada
Multidisciplinary coverage and emphasis on emerging therapeutic options, cutting edge developments and clinical research with near-term potential in clinical management

Series Description: Emerging Cancer Therapeutics is an invited review publication providing a thorough analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence; current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year, Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. ;1. Hodgkin Lymphoma; 2. Peripheral T-Cell Lymphoma; 3. Follicular Lymphoma; 4. Mantle Cell Lymphoma; 5. Aggressive B Cell Lymphomas; 6. Other Indolent NHLs; 7. Autologous SCT; 8. Allogeneric SCT; 9. Non-SCT Salvage Therapy
Published: DemosMed on
ISBN: 9781936287789
List price: $85.00
Read on Scribd mobile: iPhone, iPad and Android.
Availability for Lymphomas
With a 30 day free trial you can read online for free
  1. This book can be read on up to 6 mobile devices.

Related Articles

2 min read

New Frontiers in Breast Cancer

TERRIFYING AS THE C WORD CAN BE, breast cancer today means something very different than it did a decade ago. Doctors know more than ever about what causes cancer in the first place and when it’s best to screen for the disease as well as which cancers are more likely to spread aggressively and which may be able to be monitored and left alone. This knowledge will only grow more refined in the years to come, thanks in part to a handful of landmark studies launched this year. Mounting evidence shows that the tendency to respond to every breast cancer with every treatment option available—surgery
2 min read

Personalization Will Change the Avenues of Treatment

TODAY THE VAST MAJORITY OF WOMEN diagnosed with breast cancer receive surgery of some kind, radiation and chemotherapy, regardless of the prognosis or stage of their disease. “How do I know my cancer isn’t going to be the one that spreads?” is a question every woman grapples with, says Dr. Mehra Golshan, a cancer surgeon at Boston’s Brigham and Women’s Hospital. That’s why many women and their doctors choose to throw every treatment option available at their cancer. But that aggressive approach is, in many cases, overkill. Difficult as it may be for doctors and patients to stomach, in some ca
7 min read

Cancer Isn’t a Logic Problem

A year ago, Joe Biden launched his “cancer moonshot,” a major national push to improve the prevention, detection, and treatment of cancer, a plan that was widely recognized to be incremental. “I believe that we need an absolute national commitment to end cancer as we know it,” Biden said while he was on his tour to cancer centers at Penn and Duke University. “I’m not naïve. I didn’t think we could ‘end cancer.’ I’m not looking for a silver bullet. There is none.” Many thought the “moonshot” risked casting the solution to cancer as an engineering problem. In his op-ed in the New York Times last